PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe · MCAZ

INACTIVATED POLIOMYELITIS VACCINE TYPES 1,2,3

POLIOMYELITIS (TYPES 1,2,3; INACTIVATED)

2016/18.2/5226 VACCINE 40; 8; 32 D ANTIGEN

What it does

Poliomyelitis is a viral disease that can cause paralysis. Vaccination is key to prevention.

Commonly used for: poliomyelitis (polio)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
2016/18.2/5226
Registration date
2016-06-22
Expiry date
2029-08-06
Status
PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.)
Active ingredient
POLIOMYELITIS (TYPES 1,2,3; INACTIVATED)
Dosage form
VACCINE
Strength
40; 8; 32 D ANTIGEN
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Bilthoven Biologicals
Applicant / LTR
BILTHOVEN BIOLOGICALS B.V,
Country of origin
-
Manufacturer location
Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, Netherlands

Source: Medicines Control Authority of Zimbabwe · fetched 2026-04-18 08:22:08 · updated 2026-07-12 04:30:07

Disclaimer: This information is sourced from Medicines Control Authority of Zimbabwe (Zimbabwe). Always consult a qualified healthcare professional before using any medication.

About this medicine

Poliomyelitis is a viral disease that can cause paralysis. Vaccination is key to prevention.

What it treats

  • poliomyelitis (polio)

How it works

Vaccines stimulate the immune system to recognize and fight the poliovirus, preventing infection.

Who it's for

The vaccine is recommended for children and individuals at risk of exposure to the virus.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: poliomyelitis

Poliomyelitis, commonly known as polio, is an infectious disease caused by the poliovirus. It primarily affects children under five years of age and can lead to paralysis, respiratory issues, and in severe cases, death. The virus is transmitted through the fecal-oral route or, less commonly, through contaminated water or food. Vaccination has significantly reduced the incidence of polio worldwide. The disease can manifest in various forms, including asymptomatic, non-paralytic, and paralytic poliomyelitis.

Indications

  • Prevention of poliomyelitis infection
  • Vaccination in children and high-risk populations

Dosage

Children: Refer to the BNF for Children for specific dosages and recommendations for vaccination schedules.

Adults: Refer to specific vaccination guidelines for adults, as dosages may vary based on risk factors and prior vaccination history.

Mechanism of action

Poliovirus enters the body through the oral route, replicating in the oropharynx and gastrointestinal tract before spreading to the central nervous system via the bloodstream. Once inside the CNS, the virus selectively infects motor neurons in the anterior horn of the spinal cord, leading to cell lysis and resulting in muscle weakness or paralysis. The immune response to the virus contributes to inflammation and further neuronal damage.

Pharmacodynamics

The poliovirus's pathogenicity is primarily due to its ability to evade the host's immune response and its selective neurotropism. The destruction of motor neurons leads to flaccid paralysis, with recovery possible in some cases as the motor neurons may regenerate. The severity of the disease correlates with the extent of neuronal involvement, which can vary widely among individuals.

Pharmacokinetics

Poliovirus is an RNA virus that does not undergo traditional pharmacokinetic processes as it is not treated with drugs. Instead, the prevention of polio relies on vaccination strategies. The inactivated poliovirus vaccine (IPV) and the oral poliovirus vaccine (OPV) are used to induce immunity. After administration, the vaccines promote the development of antibodies against the virus without causing disease.

Contra-indications

  • Hypersensitivity to the vaccine component
  • Severe immunodeficiency
  • Acute febrile illness

Adverse effects

  • Pain at injection site
  • Fever
  • Fatigue
  • Headache
  • Nausea
  • Allergic reactions

Interactions

  • Immunosuppressive therapies may reduce vaccine efficacy
  • Concomitant administration with other vaccines may affect immune response

Precautions

  • Use with caution in individuals with moderate to severe acute illness
  • Consider history of allergic reactions
  • Monitor for signs of anaphylaxis after administration

Pregnancy

Poliomyelitis vaccination is generally considered safe during pregnancy, but consult a healthcare professional.

Breast-feeding

The vaccine is considered safe for breastfeeding mothers.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

  • Inactivated poliovirus vaccine (IPV)
  • Oral poliovirus vaccine (OPV)
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.

Kenya 14 products
View all 14 in Kenya →
Tanzania 4 products
Ghana 3 products
Malawi 2 products
Zambia 2 products
Rwanda 1 product